Several brokerages have updated their recommendations and price targets on shares of Haemonetics (NYSE: HAE) in the last few weeks:

  • 2/7/2018 – Haemonetics had its price target raised by analysts at Morgan Stanley from $74.00 to $77.00. They now have an “overweight” rating on the stock.
  • 2/7/2018 – Haemonetics had its “outperform” rating reaffirmed by analysts at Barrington Research. They now have a $71.00 price target on the stock, up previously from $57.00.
  • 2/7/2018 – Haemonetics had its “outperform” rating reaffirmed by analysts at JMP Securities. They now have a $72.00 price target on the stock.
  • 2/7/2018 – Haemonetics had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $80.00 price target on the stock.
  • 2/6/2018 – Haemonetics was downgraded by analysts at TheStreet from a “b” rating to a “c+” rating.
  • 1/10/2018 – Haemonetics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Over the past month, Haemonetics has been trading above the broader industry. The company’s continued expansion in newer geographies has helped the company deliver strong results in the recent past. Meanwhile, the company’s strong cash position boosts investors’ confidence. The company is also optimistic about strong market adoption of its NexSys PCS plasmapheresis system which recently received FDA approval. Further, the raised fiscal 2018 adjusted earnings guidance is encouraging. However, we are disappointed with the fact that despite the encouraging growth in the Plasma and Hospitals, the company’s sluggish Blood Center business has been moderating overall growth of late. Also, contraction in gross and operating margin is discouraging.”
  • 1/9/2018 – Haemonetics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $70.00 price target on the stock. According to Zacks, “Over the past month, Haemonetics has been trading above the broader industry. The company’s continued expansion in newer geographies has helped the company deliver strong results in the recent past. Meanwhile, the company’s strong cash position boosts investors’ confidence. The company is also optimistic about strong market adoption of its NexSys PCS plasmapheresis system which recently received FDA approval. Further, the raised fiscal 2018 adjusted earnings guidance is encouraging. However, we are disappointed with the fact that despite the encouraging growth in the Plasma and Hospitals, the company’s sluggish Blood Center business has been moderating overall growth of late. Also, contraction in gross and operating margin is discouraging.”
  • 1/8/2018 – Haemonetics had its price target raised by analysts at Jefferies Group LLC from $18.00 to $75.00. They now have a “buy” rating on the stock.
  • 1/2/2018 – Haemonetics was upgraded by analysts at Raymond James Financial, Inc. from an “underperform” rating to a “market perform” rating.
  • 1/2/2018 – Haemonetics was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $51.00 price target on the stock.

Haemonetics Co. (HAE) traded up $0.18 on Thursday, reaching $69.91. 810,989 shares of the company’s stock traded hands, compared to its average volume of 469,370. The company has a quick ratio of 1.51, a current ratio of 1.82 and a debt-to-equity ratio of 0.14. The firm has a market cap of $3,548.92, a PE ratio of -205.61, a PEG ratio of 4.58 and a beta of 1.06. Haemonetics Co. has a 52-week low of $36.83 and a 52-week high of $72.33.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.18. Haemonetics had a negative net margin of 1.94% and a positive return on equity of 12.39%. The firm had revenue of $234.04 million during the quarter, compared to analysts’ expectations of $227.79 million. During the same quarter last year, the company posted $0.43 EPS. The company’s quarterly revenue was up 2.7% compared to the same quarter last year. sell-side analysts expect that Haemonetics Co. will post 1.85 EPS for the current fiscal year.

In other news, Director Susan Bartlett Foote sold 16,926 shares of Haemonetics stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $54.19, for a total transaction of $917,219.94. Following the completion of the sale, the director now owns 27,313 shares in the company, valued at approximately $1,480,091.47. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Dan Goldstein sold 4,691 shares of Haemonetics stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $54.93, for a total transaction of $257,676.63. Following the sale, the chief accounting officer now owns 3,747 shares of the company’s stock, valued at approximately $205,822.71. The disclosure for this sale can be found here. In the last quarter, insiders have sold 54,486 shares of company stock valued at $3,050,827. 1.20% of the stock is owned by corporate insiders.

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Receive News & Ratings for Haemonetics Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Co and related companies with MarketBeat.com's FREE daily email newsletter.